Tildrakizumab-Asmn (Ilumya™)

Ilumya (tildrakizumab‑asmn) is covered for adults (≥18) with FDA‑approved moderate‑to‑severe plaque psoriasis who are candidates for systemic therapy or phototherapy, and is not covered for pediatric patients or non‑FDA indications. Initial approval requires a 3‑month trial of (or intolerance to) at least one biologic or traditional systemic agent or a contraindication to methotrexate, prescriber/consultation by a dermatologist, an initial 3‑month authorization (renewals 12 months) with documented response for reauthorization, and dosing limited to 100 mg SC at weeks 0 and 4 then no more often than every 12 weeks.

"Ilumya is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy."

Sign up to see full coverage criteria, indications, and limitations.